NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 8, 2020 ARTICLES OF ASSOCIATION PROXY FORM SHARE BUY-BACK CONTRACT Dear …
[Read more...] about NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 8, 2020
Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29
Safety and efficacy data from Phase II clinical trial of nomacopan in adults with mild to moderate BPThe Phase II data was the basis for the agreement of the …
Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia
FDA clearance received to proceed with investigator-led multi-center double blind randomized clinical study in the U.S. with nomacopan following prior expanded …
Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid
The EMA and the FDA have both agreed to a Phase III randomized placebo-controlled study with nomacopan in moderate to severe bullous pemphigoid (BP) patients …
Akari Therapeutics to Participate in Two September Virtual Investor Conferences
NEW YORK and LONDON, September 10, 2020 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to …
[Read more...] about Akari Therapeutics to Participate in Two September Virtual Investor Conferences
